Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

Phase 1 Completed 16 enrolled M.D. Anderson Cancer Center Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of gimatecan that can be given to treat myelodysplastic syndrome (MDS).

Timeline

Start: 2007-08
Primary completion: 2014-05
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gimatecan	Small molecule	0.6 mg	Oral

Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

Summary

Timeline

Drugs

Indications